Aardvark Therapeutics (AARD) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 55.8% versus a loss of 72.5%. Foghorn Therapeutics is the larger company by market cap ($118.2 million vs $103.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | FHTX |
|---|---|---|
| Share price | $4.71 | $1.99 |
| Market cap | $103.08M | $118.18M |
| 1-day change | -5.04% | -4.78% |
| YTD return | -64.11% | -63.15% |
| 1-year return | -72.50% | -55.78% |
| 5-year return | — | -83.93% |
| EPS (TTM) | $-3.21 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $7.61 |
| 52-week low | $3.35 | $1.79 |
| Distance from 52-week high | -72.38% | -73.85% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +135.88% | +201.51% |
| Average volume | 208.11K | 629.61K |
| Shares outstanding | 21.88M | 59.39M |
| Employees | 28 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed AARD by 16.7 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
AARD vs FHTX FAQ
Which is bigger, Aardvark Therapeutics or Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $118.18M compared with $103.08M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or FHTX?
FHTX returned -55.78% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Foghorn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.